Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB08D3)

Drug Name
Bidentate ligands of Markush derivative 1 Drug Info
Synonyms PMID28117607-Compound-35
Cross-matching ID
TTD Drug ID
DMB08D3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Leucine-rich repeat kinase 2 (LRRK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DNL151 DMZT89C Parkinson disease 8A00.0 Phase 1 [2]
DNL201 DMFEORD Parkinson disease 8A00.0 Phase 1 [2]
BIIB094 DMLUO5K Parkinson disease 8A00.0 Phase 1 [3]
Pyrrolo-pyridine derivative 2 DMVNY5I N. A. N. A. Patented [1]
Bidentate ligands of Markush derivative 2 DM2QNMC N. A. N. A. Patented [1]
Oxindole derivative 3 DM0ENF3 N. A. N. A. Patented [1]
Aminopyridine derivative 3 DMSLJE8 N. A. N. A. Patented [1]
Fused thiophene derivative 1 DMV7IX4 N. A. N. A. Patented [1]
Oxindole derivative 4 DM3U58I N. A. N. A. Patented [1]
Pyrrolo-pyrimidine derivative 8 DMZH27I N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Mitogen-activated protein kinase (MAPK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GBL-310 DM2IFJQ Keratosis ED56 Phase 2 [4]
LTT462 DM94E6W Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
PF-07799544 DMAO10K Aggressive cancer 2A00-2F9Z Phase 1 [6]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [7]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [7]
Bidentate ligands of Markush derivative 2 DM2QNMC N. A. N. A. Patented [1]
PMID25991433-Compound-Q1 DMEMSB2 N. A. N. A. Patented [7]
PMID25991433-Compound-C3 DMSKWBE N. A. N. A. Patented [7]
PMID25991433-Compound-J6 DMOWULJ N. A. N. A. Patented [7]
PMID25991433-Compound-L DM5U8WT N. A. N. A. Patented [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leucine-rich repeat kinase 2 (LRRK2) TTK0FEA LRRK2_HUMAN Inhibitor [1]
Mitogen-activated protein kinase (MAPK) TTVOE6D NOUNIPROTAC Inhibitor [1]

References

1 Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of Ionis
4 WO patent application no. 2010,0456,51, Methods for analyzing drug response.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
7 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.